EP0671951A4 - Anticorps humanises reagissant avec l-selectine. - Google Patents

Anticorps humanises reagissant avec l-selectine.

Info

Publication number
EP0671951A4
EP0671951A4 EP94903357A EP94903357A EP0671951A4 EP 0671951 A4 EP0671951 A4 EP 0671951A4 EP 94903357 A EP94903357 A EP 94903357A EP 94903357 A EP94903357 A EP 94903357A EP 0671951 A4 EP0671951 A4 EP 0671951A4
Authority
EP
European Patent Office
Prior art keywords
selectin
humanized antibodies
antibodies reactive
reactive
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94903357A
Other languages
German (de)
English (en)
Other versions
EP0671951A1 (fr
Inventor
Man Sung Co
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of EP0671951A1 publication Critical patent/EP0671951A1/fr
Publication of EP0671951A4 publication Critical patent/EP0671951A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP94903357A 1992-12-01 1993-11-30 Anticorps humanises reagissant avec l-selectine. Withdrawn EP0671951A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98394692A 1992-12-01 1992-12-01
US983946 1992-12-01
PCT/US1993/011612 WO1994012215A1 (fr) 1992-12-01 1993-11-30 Anticorps humanises reagissant avec l-selectine

Publications (2)

Publication Number Publication Date
EP0671951A1 EP0671951A1 (fr) 1995-09-20
EP0671951A4 true EP0671951A4 (fr) 1997-05-21

Family

ID=25530200

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94903357A Withdrawn EP0671951A4 (fr) 1992-12-01 1993-11-30 Anticorps humanises reagissant avec l-selectine.

Country Status (12)

Country Link
EP (1) EP0671951A4 (fr)
JP (1) JPH08503617A (fr)
KR (1) KR100371784B1 (fr)
AU (1) AU689090B2 (fr)
CA (1) CA2149025A1 (fr)
CZ (1) CZ140195A3 (fr)
FI (1) FI952658A0 (fr)
HU (1) HUT71790A (fr)
NO (1) NO952160L (fr)
PL (1) PL309249A1 (fr)
RU (1) RU2151612C1 (fr)
WO (1) WO1994012215A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
AU6155896A (en) * 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
AU746888B2 (en) * 1995-08-17 2002-05-02 Protein Design Labs, Inc. Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
CZ45498A3 (cs) * 1995-08-17 1999-01-13 Protein Design Labs, Inc. Použití antiselektinových protilátek pro výrobu farmaceutických kompozic určených pro prevenci mnohačetného selhání orgánů v důsledku vícečetného úrazu a pro prevenci akutního poškození orgánů po aplikaci mimotělního krevního objehu
ATE358492T1 (de) * 1996-09-27 2007-04-15 Univ Columbia Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
WO1999043353A2 (fr) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Therapie combinee par anti-selectine et immunodepresseur
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
CN101500608A (zh) 2006-06-08 2009-08-05 中外制药株式会社 炎性疾病的预防或治疗药
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CL2008002886A1 (es) 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
KR102469853B1 (ko) 2008-04-11 2022-11-22 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
WO2010107110A1 (fr) 2009-03-19 2010-09-23 中外製薬株式会社 Variant d'une région constante d'anticorps
CA2806233C (fr) * 2010-07-26 2021-12-07 Trianni, Inc. Animaux transgeniques et methodes d'utilisation
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
PT2654781T (pt) * 2010-12-21 2018-05-02 Oklahoma Med Res Found Anticorpos anti-p-selectina e métodos para a sua utilização e identificação
ES2758974T5 (es) 2011-02-25 2023-06-08 Regeneron Pharma Ratones ADAM6
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
KR101924805B1 (ko) 2011-12-20 2018-12-04 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
KR102381716B1 (ko) 2012-06-12 2022-04-01 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
SG11201607203XA (en) 2014-03-21 2016-09-29 Regeneron Pharma Non-human animals that make single domain binding proteins
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
CA2979702A1 (fr) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Animaux non humains qui selectionnent des regions variables de chaines legeres qui se lient a l'antigene
RU2749512C2 (ru) 2015-04-14 2021-06-11 Чугаи Сейяку Кабусики Кайся Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
WO2021100794A1 (fr) 2019-11-20 2021-05-27 中外製薬株式会社 Préparation pharmaceutique comprenant un anticorps

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011018A1 (fr) * 1990-12-19 1992-07-09 Protein Design Labs, Inc. Immunoglobulines humanisees ameliorees

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011018A1 (fr) * 1990-12-19 1992-07-09 Protein Design Labs, Inc. Immunoglobulines humanisees ameliorees

Also Published As

Publication number Publication date
WO1994012215A1 (fr) 1994-06-09
NO952160D0 (no) 1995-05-31
AU5732794A (en) 1994-06-22
JPH08503617A (ja) 1996-04-23
HUT71790A (en) 1996-02-28
NO952160L (no) 1995-07-31
EP0671951A1 (fr) 1995-09-20
AU689090B2 (en) 1998-03-26
RU2151612C1 (ru) 2000-06-27
KR100371784B1 (ko) 2003-07-22
FI952658A (fi) 1995-05-31
CZ140195A3 (en) 1996-06-12
PL309249A1 (en) 1995-10-02
HU9501564D0 (en) 1995-07-28
CA2149025A1 (fr) 1994-06-09
FI952658A0 (fi) 1995-05-31

Similar Documents

Publication Publication Date Title
EP0671951A4 (fr) Anticorps humanises reagissant avec l-selectine.
AU4025193A (en) Humanized C-erbB-2 specific antibodies
IL111926A0 (en) Humanized antibodies and uses thereof
AU4618193A (en) Humanized antibodies
EP0627932A4 (fr) Nouvelle structure d&#39;anticorps.
EP0604033A3 (fr) Arrangement d&#39;étanchéité.
EP0676966A4 (fr) Anticorps diriges contre les epitopes associes par liaison.
AU5732694A (en) Humanized antibodies reactive with cd18
EP0578515A3 (fr) Anticorps monoclonaux humanisés.
GB9412166D0 (en) Retargetting antibodies
GB9313288D0 (en) The super bottle
EP0580859A4 (en) Anti-eda monoclonal antibody
EP0506523A3 (en) Monoclonal antibodies
AU8547291A (en) Monoclonal antibodies against tenascin
GB2246827B (en) Pipe stopper
EP0654532A4 (fr) Anticorps monoclonal antimucoglycoproteine.
EP0640621A3 (fr) Anticorps monoclonal anti-thrombine.
EP0671924A4 (fr) Composes semblables a la digitaline.
ZA931100B (en) A 90K tumor-associated antigen, IR-95.
EP0597211A3 (en) Optical duplexer.
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
EP0668923A4 (fr) Anticorps monoclonal.
ZA928880B (en) Tumor associated monoclonal antibody 88BV59.
IE901956L (en) Monoclonal antibody.
AU4801093A (en) Monoclonal antibodies specific for 3&#39;,6&#39;-isold1 ganglioside

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950630

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19970404

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTEIN DESIGN LABS, INC.

17Q First examination report despatched

Effective date: 20000407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041126